#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

OncoQuest appoints Eliel Bayever as chief medical officer

Share on Twitter Share on LinkedIn
Staff Writer | Edmonton, AB, Canada | May 15, 2018
OncoQuestOncoQuest, a privately held, cancer immunotherapy company, announced the appointment of Eliel Bayever as chief medical officer.
Dr. Bayever has spent almost 20 years in the biopharmaceutical industry developing both biologics and small molecule oncology drugs globally.

Prior to joining OncoQuest, Dr. Bayever was Vice President and Head of Oncology at Glenmark Pharmaceuticals, responsible for leading the effort to develop novel biologics for cancer immunotherapy.

Prior to that, he has was Vice President, Medical, at Merrimack Pharmaceuticals, where he led the registration study, regulatory submission and global approval of ONIVYDE as a post-gemcitabine treatment of pancreatic cancer.

Dr. Bayever has also held senior medical positions at Johnson & Johnson, Wyeth (now Pfizer), Human Genome Sciences (now Glaxo Smith Kline), and Bayer focusing primarily on oncology therapeutics, as well as related devices and diagnostics.

Before joining Bayer, he was Associate Professor of Pediatrics at The George Washington School of Medicine and Health Services and Director of the Hematopoietic Stem Cell Transplantation Program, a senior investigator at the Center for Cancer and Transplantation Biology and a member of the Institutional Biosafety Committee at the Children's National Medical Center in Washington, DC.

Dr. Bayever has was also on staff at the University of Nebraska Medical Center, and the Children's Hospital of Philadelphia.

He received his medical degree from the Medical School of the University of Witwatersrand in South Africa, is a Member of the Royal College of Physicians of the United Kingdom after time spent at King's College Hospital in London and completed a Fellowship in Pediatric Hematology-Oncology at UCLA.

Dr. Bayever has published over 30 research articles in peer-reviewed journals and contributed 15 editorials, reviews and chapters.